MannKind - Afrezza Sales Improve Slightly, But Not Enough To Excite Investors Feb. 3, 2017 4:09 PM ET Spencer Osborne •Afrezza scripts remain below 300. •Company is shifting to new sales force. •Reverse Split is center stage. http://seekingalpha.com/article/4042601-mannkind-afrezza-sales-improve-slightly-enough-excite-investors?app=1&auth_param=1vat:1c99sci:0c3d38a71440b519e8a1f497c1ba64be&uprof=51